Metabolic HealthGLP-1 Drugs Show Promise Against Addiction, but Trials Deliver Mixed Results
GLP-1 drugs, commonly used for diabetes and weight management, may also help reduce substance-related harms. This systematic review included 11 studies covering alcohol, tobacco, opioids, and broader substance use outcomes. Observational studies linked treatment to fewer alcohol-related hospitalizations and lower risks of tobacco use disorder and opioid overdose. However, randomized alcohol trials gave mixed results, so these associations do not establish that the drugs prevent addiction or overdose. The review also reported weight loss, improved blood sugar measures, and no pattern of increasing serious adverse events. These findings support further research, not replacing established addiction treatment. Patients should not assume that taking a GLP-1 drug protects them against substance-related harm. This summary is based on the abstract only, which provides limited study details and contains unclear numerical formatting.
